ATE331530T1 - Proteasom-influenzavirus-impfstoffzusammensetzu g - Google Patents

Proteasom-influenzavirus-impfstoffzusammensetzu g

Info

Publication number: ATE331530T1
Authority: AT; Austria
Prior art keywords: proteasome; influenza virus; vaccine composition; virus vaccine; vaccines
Prior art date: 2000-02-15

Application number

AT01910923T

Other languages

English (en)

Inventor

David S Burt

George H Lowell

Gregory Lee White

Louis F Fries Iii

Kirkor Torossian

David Hugh Jones

Martin Plante

Original Assignee

Id Biomedical Corp Quebec

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-15

Filing date

2001-02-15

Publication date

2006-07-15

2001-02-15 Application filed by Id Biomedical Corp Quebec filed Critical Id Biomedical Corp Quebec

2006-07-15 Application granted granted Critical

2006-07-15 Publication of ATE331530T1 publication Critical patent/ATE331530T1/de

Links

229940124873 Influenza virus vaccine Drugs 0.000 title 1
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title 1
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title 1
229960005486 vaccine Drugs 0.000 abstract 3
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 1
206010022000 influenza Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT01910923T 2000-02-15 2001-02-15 Proteasom-influenzavirus-impfstoffzusammensetzu g ATE331530T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US18247600P	2000-02-15	2000-02-15

Publications (1)

Publication Number	Publication Date
ATE331530T1 true ATE331530T1 (de)	2006-07-15

Family

ID=22668645

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01910923T ATE331530T1 (de)	2000-02-15	2001-02-15	Proteasom-influenzavirus-impfstoffzusammensetzu g

Country Status (11)

Country	Link
US (3)	US6743900B2 (de)
EP (1)	EP1255561B1 (de)
JP (2)	JP3980884B2 (de)
AT (1)	ATE331530T1 (de)
AU (4)	AU3847801A (de)
CA (1)	CA2400468C (de)
DE (1)	DE60121136T2 (de)
ES (1)	ES2267724T3 (de)
IL (2)	IL150602A0 (de)
NO (1)	NO20023829D0 (de)
WO (1)	WO2001060402A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1211192A (zh) *	1995-09-18	1999-03-17	美国陆军医疗材料研究指挥部	生产非共价复合的多价蛋白体亚基疫苗的改进方法
US7022683B1 (en)	1998-05-13	2006-04-04	Carrington Laboratories, Inc.	Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
CA2400468C (en) *	2000-02-15	2012-12-18	Intellivax International Inc.	Proteosome influenza vaccine
US7524509B2 (en) *	2001-03-09	2009-04-28	Id Biomedical Corporation Of Quebec	Proteosome-liposaccharide vaccine adjuvant
AU2002346424A1 (en)	2001-11-19	2003-06-10	Becton, Dickinson And Company	Pharmaceutical compositions in particulate form
NZ536859A (en) *	2002-05-14	2007-11-30	Chiron Srl	Mucosal combination vaccines for bacterial meningitis
US7255867B2 (en) *	2002-11-15	2007-08-14	Id Biomedical Corporation Of Quebec	Vaccine
US7491395B2 (en)	2002-11-20	2009-02-17	Bestewil Holding B.V.	Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
AU2003296592A1 (en)	2002-11-20	2004-06-15	Crucell Holland B.V.	Antigen-complexes
EP1447080A1 (de)	2003-02-13	2004-08-18	Bestewil Holding B.V.	Methode zur Herstellung von Virosomen-artigen Partikeln
AR056245A1 (es)	2003-06-19	2007-10-03	Bestewil Holding Bv	Membranas virales reconstituidas funcionales que contienen un coadyuvante
US7368537B2 (en) *	2003-07-15	2008-05-06	Id Biomedical Corporation Of Quebec	Subunit vaccine against respiratory syncytial virus infection
US20050152919A1 (en) *	2003-09-15	2005-07-14	Id Biomedical Corporation Of Quebec	Measles subunit vaccine
GB0323231D0 (en) *	2003-10-03	2003-11-05	Chiron Srl	Immunodiffusion assays
WO2005042017A1 (en)	2003-10-22	2005-05-12	Id Biomedical Corporation Of Quebec	Compositions and methods for activating innate and allergic immunity
CN101039691B (zh) *	2004-06-25	2013-07-31	魁北克益得生物医学公司	用于治疗神经疾病的组合物和方法
EP1778283A2 (de) *	2004-06-30	2007-05-02	ID Biomedical Corporation of Quebec	Vaccinzusammensetzungen zur behandlung von coronavirusinfektion
US20060275170A1 (en) *	2005-06-02	2006-12-07	Mahmoud Ameri	Method for terminal sterilization of transdermal delivery devices
US8535683B2 (en) *	2006-03-22	2013-09-17	Abbott Biologicals B.V.	Intranasal or inhalational administration of virosomes
US20080038294A1 (en) *	2006-03-22	2008-02-14	Kersten Alexander J	Intranasal or inhalational administration of virosomes
WO2008073490A1 (en) *	2006-12-12	2008-06-19	Carrington Laboratories Inc.,	Purification of influenza viral antigens
CN101679974B (zh)	2007-03-27	2015-09-30	航道生物技术有限责任公司	包含抗体替代轻链序列的构建体和文库
JP5518041B2 (ja) *	2008-03-18	2014-06-11	ノバルティスアーゲー	インフルエンザウイルスワクチン抗原の調製における改良
JP2011516423A (ja)	2008-03-28	2011-05-26	シーレーンバイオテクノロジーズ，エルエルシー	ウイルス抗原に対する中和分子
KR100966566B1 (ko)	2009-01-29	2010-06-29	엘지전자 주식회사	효율적인 공용 ｅ-ｄｃｈ 관리를 위한 신호 전송 기법
CA2761681A1 (en)	2009-05-13	2010-11-18	Sea Lane Biotechnologies, Llc	Neutralizing molecules to influenza viruses
WO2010144797A2 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Influenza vaccines with enhanced immunogenicity and uses thereof
CA2803282C (en)	2009-07-06	2018-05-01	David E. Anderson	Methods for preparing vesicles and formulations produced therefrom
JP5854559B2 (ja)	2009-07-06	2016-02-09	ヴァリエーションバイオテクノロジーズインコーポレイテッド	小胞を調製する方法及びこれから製造される製剤
WO2011106525A2 (en)	2010-02-26	2011-09-01	The Brigham And Women's Hospital, Inc.	Methods of treating cerebral amyloid angiopathy
CN114010776A (zh)	2010-06-09	2022-02-08	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
WO2012006367A2 (en)	2010-07-06	2012-01-12	Variation Biotechnologies, Inc.	Compositions and methods for treating influenza
US10736844B2 (en)	2011-01-13	2020-08-11	Variation Biotechnologies Inc.	Compositions and methods for treating viral infections
BR112013018074A2 (pt)	2011-01-13	2020-12-01	Variation Biotechnologies, Inc.	métodos para a preparação de vesículas e formulações produzidas a partir dessas
EP2736928B1 (de)	2011-07-28	2019-01-09	i2 Pharmaceuticals, Inc.	Gegen erbb3-gerichtete sur-bindende proteine
US20140328876A1 (en)	2011-11-18	2014-11-06	Variation Biotechnologies Inc.	Synthetic derivatives of mpl and uses thereof
US9975956B2 (en)	2011-12-22	2018-05-22	I2 Pharmaceuticals, Inc.	Surrogate binding proteins which bind DR4 and/or DR5
AU2013208693B2 (en)	2012-01-12	2017-12-07	Variation Biotechnologies Inc.	Compositions and methods for treating viral infections
EP2806894A4 (de)	2012-01-27	2015-11-04	Variation Biotechnologies Inc	Verfahren und zusammensetzungen für therapeutika
KR101601393B1 (ko)	2014-02-20	2016-03-09	현대자동차주식회사	차량용 비상 버튼
CA3040288A1 (en)	2016-11-04	2018-07-12	Baxalta Incorporated	Adeno-associated virus purification methods
WO2019035972A1 (en) *	2017-08-16	2019-02-21	Georgia State University Research Foundation, Inc.	SEQUENTIAL IMMUNIZATIONS WITH HIV-1 ENV VIRUS TYPE PARTICLES
CA3208643A1 (en)	2021-01-18	2022-07-21	Conserv Bioscience Limited	Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4707543A (en)	1985-09-17	1987-11-17	The United States Of America As Represented By The Secretary Of The Army	Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en)	1987-06-23	1998-03-10	Lowell; George H.	Immuno-potentiating systems for preparation of immunogenic materials
DE3830496C1 (de) *	1988-09-08	1996-09-19	Daimler Benz Aerospace Ag	Vorrichtung zum Erkennen und Verfolgen von Objekten
SK279209B6 (sk) *	1992-12-21	1998-08-05	Virologický Ústav Sav	Bivalentné imunogény a spôsob ich prípravy
US5576016A (en)	1993-05-18	1996-11-19	Pharmos Corporation	Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en)	1993-10-29	1999-10-05	Pharmos Corporation	Submicron emulsions as vaccine adjuvants
WO1995011700A1 (en)	1993-10-29	1995-05-04	Pharmos Corp.	Submicron emulsions as vaccine adjuvants
CN1211192A (zh)	1995-09-18	1999-03-17	美国陆军医疗材料研究指挥部	生产非共价复合的多价蛋白体亚基疫苗的改进方法
ES1032221Y (es) *	1995-10-04	1996-11-01	Ferre Jose Manuel Rodriguez	Tobogan componible perfeccionado para uso infantil.
AU739723B2 (en) *	1996-07-10	2001-10-18	Government Of The United States Of America, As Represented By The Secretary Of The Army, The	Protein and peptide vaccines for inducing mucosal immunity
JP3426177B2 (ja) *	1999-12-28	2003-07-14	明智セラミックス株式会社	鋳造用ストッパー
CA2400468C (en) *	2000-02-15	2012-12-18	Intellivax International Inc.	Proteosome influenza vaccine
US6726292B1 (en) *	2000-07-27	2004-04-27	Daimlerchrysler Corporation	Full off-set two-piece fiber reinforced composite wheel using spoke or web area box sections

2001
- 2001-02-15 CA CA2400468A patent/CA2400468C/en not_active Expired - Lifetime
- 2001-02-15 WO PCT/US2001/005222 patent/WO2001060402A2/en not_active Ceased
- 2001-02-15 IL IL15060201A patent/IL150602A0/xx unknown
- 2001-02-15 AU AU3847801A patent/AU3847801A/xx active Pending
- 2001-02-15 AU AU2001238478A patent/AU2001238478C1/en not_active Expired
- 2001-02-15 DE DE60121136T patent/DE60121136T2/de not_active Expired - Lifetime
- 2001-02-15 AT AT01910923T patent/ATE331530T1/de not_active IP Right Cessation
- 2001-02-15 JP JP2001559498A patent/JP3980884B2/ja not_active Expired - Lifetime
- 2001-02-15 US US09/788,280 patent/US6743900B2/en not_active Expired - Lifetime
- 2001-02-15 EP EP01910923A patent/EP1255561B1/de not_active Expired - Lifetime
- 2001-02-15 ES ES01910923T patent/ES2267724T3/es not_active Expired - Lifetime
2002
- 2002-07-04 IL IL150602A patent/IL150602A/en not_active IP Right Cessation
- 2002-08-13 NO NO20023829A patent/NO20023829D0/no not_active Application Discontinuation
2004
- 2004-02-03 US US10/771,737 patent/US7399840B2/en not_active Expired - Lifetime
2006
- 2006-05-12 AU AU2006202003A patent/AU2006202003A1/en not_active Abandoned
- 2006-10-30 JP JP2006294115A patent/JP2007051157A/ja active Pending
2008
- 2008-06-24 US US12/144,722 patent/US20080260781A1/en not_active Abandoned
2009
- 2009-04-27 AU AU2009201657A patent/AU2009201657A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US6743900B2 (en)	2004-06-01
AU2001238478C1 (en)	2006-11-09
EP1255561A2 (de)	2002-11-13
NO20023829L (no)	2002-08-13
IL150602A0 (en)	2003-02-12
US20010053368A1 (en)	2001-12-20
DE60121136D1 (de)	2006-08-10
WO2001060402A2 (en)	2001-08-23
AU3847801A (en)	2001-08-27
AU2009201657A1 (en)	2009-05-21
US20080260781A1 (en)	2008-10-23
DE60121136T2 (de)	2007-06-06
JP2003522802A (ja)	2003-07-29
ES2267724T3 (es)	2007-03-16
NO20023829D0 (no)	2002-08-13
CA2400468A1 (en)	2001-08-23
EP1255561B1 (de)	2006-06-28
US7399840B2 (en)	2008-07-15
HK1052629A1 (en)	2003-09-26
AU2001238478B2 (en)	2006-06-01
AU2006202003A1 (en)	2006-06-01
US20040156867A1 (en)	2004-08-12
WO2001060402A3 (en)	2002-03-21
JP2007051157A (ja)	2007-03-01
JP3980884B2 (ja)	2007-09-26
CA2400468C (en)	2012-12-18
IL150602A (en)	2010-12-30

Legal Events

Date	Code	Title	Description
2006-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE331530T1 (de)	2006-07-15	Proteasom-influenzavirus-impfstoffzusammensetzu g
DE60039198D1 (de)	2008-07-24	Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
CY1110585T1 (el)	2015-04-29	ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
MY126588A (en)	2006-10-31	Intranasal influenza virus vaccine
DK1326636T3 (da)	2007-04-30	Vaccinesammensætning
ATE491467T1 (de)	2011-01-15	Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
AR014182A1 (es)	2001-02-07	Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
EA200801798A1 (ru)	2009-06-30	Виросомоподобные везикулы, содержащие антигены, производные от gp41
MXPA02005639A (es)	2004-09-10	Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
MXPA05009580A (es)	2005-10-19	Vacuna contra el virus de la influenza.
DE60335186D1 (de)	2011-01-13	Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
DE60144240D1 (de)	2011-04-28	Zusammensetzung mit immunogenen mikroteilchen
CY1108789T1 (el)	2014-04-09	Καθαρισμος αντιγονων hbv για χρηση σε εμβολια
ATE511855T1 (de)	2011-06-15	Adjuvansformulierung zur scheimhaut-applikation
BR0010711A (pt)	2002-02-13	Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
EA200801251A1 (ru)	2008-12-30	Вакцины против гриппа, адсорбированные на алюминиевых адъювантах, для немедленного приёма
EP1439856A4 (de)	2005-01-19	Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
DE69637435D1 (de)	2008-03-27	Saponin-zusammensetzungen und deren verwendung
EP1721618A3 (de)	2007-01-10	Proteasom-influenzavirus-impfstoffzusammensetzung
AR020852A1 (es)	2002-05-29	Antigenos de vacuna de leptospira para la prevencion de leptospirosis
AR034771A1 (es)	2004-03-17	Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
WO2002030458A8 (en)	2002-07-18	Yersinia adhesion protein as vaccine adjuvant
DK1490100T3 (da)	2012-03-12	Kombinerede DNA/proteinvaccinepræparater
AR037908A1 (es)	2004-12-22	Una biomasa en particulas de embrion aviar para la produccion de antigenos de virus
WO2002072622A3 (en)	2003-04-17	Vaccine antigens against infection by chlamydia trachomatis